Clinical Study on Qili Qiangxin Capsule(芪苈强心胶囊)in Treatment of Chronic Heart Failure
Objective To observe the clinical effect of Qili Qiangxin Capsule(芪苈强心胶囊)on chronic heart failure.Meth-od A total of 120 patients with chronic heart failure hospitalized in the Department of Cardiovascular Medicine of the hospital from October 2021 to October 2022 were selected as the study subjects.According to different treatment methods,all patients were divided into conventional treatment group and Qili Qiangxin Capsule group,with 60 cases in each.The conventional treat-ment was treated with conventional Western medicine,and Qili Qiangxin Capsule was also given to Qili Qiangxin Capsule group on the basis of the conventional Western medicine.The clinical effects and adverse reactions of the two groups were observed,and the changes of clinical symptoms,cardiac function,hemodynamics and vascular endothelial function before and after intervention were compared.Results The total effective rates of Qili Qiangxin Capsule group and conventional treatment group were 78.33％(47/60)and 91.67％(55/60),respectively,and the total effective rate of Qili Qiangxin Capsule group was significantly higher than that of the conventional treatment(P＜0.05).Before intervention,there was no significant difference in TCM syndrome scores between the two groups(P＞0.05).After 8 weeks of intervention,the scores of palpitation,shortness of breath,fatigue and lower limb edema were significantly reduced in Qili Qiangxin Capsule group(P＜0.01).After 8 weeks of intervention,the value of left ventricular ejection fractions(LVEF)in Qili Qiangxin Capsule group was significantly higher than that of the conventional treatment group,while the values of left ventricular end-systolic dimension(LVESD)and left ventricular end-diastolic dimen-sion(LVEDD)were significantly lower(P＜0.01).Compared with those of the conventional treatment group,the levels of vascu-lar endothelial growth factor(VEGF)and nitric oxide(NO)were significantly increased,while endothelin-1(ET-1)levels were significantly decreased in Qili Qiangxin Capsule group(P＜0.01).After 8 weeks of intervention,the values of cardiac index(CI),stroke output(SV)and cardiac output(CO)in Qili Qiangxin Capsule group were significantly higher than those of the con-ventional treatment group(P＜0.01).Compared with those of the conventional treatment group,6-minute walking test(6MWT)level was significantly increased,while Minnesota Living with Heart Failure Questionnaire(MLHFQ)score was significantly de-creased in the Qili Qiangxin Capsule group(P＜0.01).The vital signs of the two groups were stable during the intervention,and the main adverse reactions included nausea and vomiting,dyspepsia,dizziness and fatigue,etc.The incidence of total adverse re-actions in the two groups was 8.33％(5/60)and 11.67％(7/60),respectively,and the difference was not statistically significant(P＞0.05).Conclusion Qili Qiangxin Capsule combined with conventional Western medicine treatment can significantly improve the clinical efficacy and the cardiac function and symptoms of heart failure patients,regulate the hemodynamics,protect the vascu-lar endothelial function,has no increased adverse reactions and can improve the quality of life.
万方数据
维普
